Abstract: The incidence of psoriasis in HIV-infected individuals is significantly higher than in the general population, with more severe clinical manifestations, greater therapeutic challenges, and a higher tendency to relapse. In recent years, biological agents and small-molecule drugs have achieved breakthrough progress in the treatment of moderate-to-severe psoriasis， however, HIV-infected individuals are usually excluded from clinical trials. Case reports and retrospective studies have shown that lesions in HIV-positive psoriasis patients respond effectively to treatment with biological agents or small-molecule drugs, with no observed progression of HIV disease or increased risk of severe infections. The advances in the treatment of HIV-associated psoriasis using biological agents and small-molecule drugs are reviewed.

Key words: psoriasis, human immunodeficiency virus, biological agents, small molecule drug